Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory ...

The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average.

Eli Lilly’s trial testing its obesity pill found that the highest dose of the drug lowered participants weight by 10.5% ...

GLP-1 medications have been known to come with a raft of side effects, including weight loss and drastic changes to users' ...

Turning to Wall Street, the analysts’ consensus rating for Novo Nordisk is Moderate Buy, based on three Buy and four Hold ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

A growing number of patients claim popular weight loss and diabetes drugs like Ozempic can cause a rare but very serious side ...

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S.

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...